Vygoris is a new company in the UK.
We develop, acquire and market sophisticated niche pharmaceutical products.
Vygoris is a young, dynamic and vibrant company. We are driven by our ambition to deliver results – results for patients and the scientific community, results for nurses, doctors and pharmacists
Our team is continuously looking for the next opportunity, the next idea, the next development that can improve our existing products. That includes working hard with the best partners both at home and internationally.
About Us
Vygoris Ltd is a subsidiary of Substipharm, a privately owned French specialist generics company.
In 2017 we have acquired a product mainly used in secondary care (urology, Mitocin®) for use primarily in bladder cancer.
In 2018, we have acquired a second product mainly used in primary care (anti-fungal antibiotics, Nystan®)
Our aim is to introduce innovative and difficult to manufacture specialist products, in a range of therapy areas.
A proud member of:
Working closely in the Nordics with:
Part of the Substipharm Group
Products
Vygoris’ first launch in the UK is in bladder cancer.
Further information is available on the Mitocin website.
Vygoris’ second launch in the UK is in primary care.
Further information is available on the Nystan website.
